Home >> Research Area >> Sevelamer HCl

Sevelamer HCl

CAS# 152751-57-0

Sevelamer HCl

Catalog No. BCC4718----Order now to get a substantial discount!

Product Name & Size Price Stock
Sevelamer HCl: 5mg $12 In Stock
Sevelamer HCl: 10mg Please Inquire In Stock
Sevelamer HCl: 20mg Please Inquire Please Inquire
Sevelamer HCl: 50mg Please Inquire Please Inquire
Sevelamer HCl: 100mg Please Inquire Please Inquire
Sevelamer HCl: 200mg Please Inquire Please Inquire
Sevelamer HCl: 500mg Please Inquire Please Inquire
Sevelamer HCl: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Sevelamer HCl

Number of papers citing our products

Chemical structure

Sevelamer HCl

3D structure

Chemical Properties of Sevelamer HCl

Cas No. 152751-57-0 SDF Download SDF
PubChem ID 159247 Appearance Powder
Formula C6H13Cl2NO M.Wt 186.08
Type of Compound N/A Storage Desiccate at -20°C
Solubility H2O : < 0.1 mg/mL (insoluble)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Chemical Name 2-(chloromethyl)oxirane;prop-2-en-1-amine;hydrochloride
SMILES [H+].[Cl-].NCC=C.ClCC1CO1
Standard InChIKey KHNXRSIBRKBJDI-UHFFFAOYSA-N
Standard InChI InChI=1S/C3H5ClO.C3H7N.ClH/c4-1-3-2-5-3;1-2-3-4;/h3H,1-2H2;2H,1,3-4H2;1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Sevelamer HCl

DescriptionSevelamer Hcl is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

References:
[1]. Sevelamer, From Wikipedia

Sevelamer HCl Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Sevelamer HCl Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Sevelamer HCl

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 5.374 mL 26.8702 mL 53.7403 mL 107.4807 mL 134.3508 mL
5 mM 1.0748 mL 5.374 mL 10.7481 mL 21.4961 mL 26.8702 mL
10 mM 0.5374 mL 2.687 mL 5.374 mL 10.7481 mL 13.4351 mL
50 mM 0.1075 mL 0.5374 mL 1.0748 mL 2.1496 mL 2.687 mL
100 mM 0.0537 mL 0.2687 mL 0.5374 mL 1.0748 mL 1.3435 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Sevelamer HCl

Sevelamer HCl

Featured Products
New Products
 

References on Sevelamer HCl

Transient acid exposure increases sevelamer HCl phosphate binding.[Pubmed:17506513]

J Pharm Sci. 2007 Aug;96(8):2154-60.

The patient-to-patient variability in the dosing of Sevelamer HCl for phosphate control led us to test whether the binder's transient exposure to acidic environments (such as the stomach) might alter the compound so as to change its subsequent binding capacity in the more alkaline small intestine. We hypothesized that an acid milieu could either increase the reactive sites (protonated amine groups) or make the polymer more hydrophilic (hydration and swelling allowing more phosphate to reach those sites). Eight hundred milligrams of Renagel tablets were exposed to pHs 1, 2.3, and 7 (n = 7 each acidity level) for 1 h. NaCl was added to keep ionic strength the same. Measured by atomic emission phosphate uptake after 3 h at pH 7 was, respectively, 3.13 +/- 0.21, 2.72 +/- 0.35, and 1.85 +/- 0.46 mequiv./g (p = 0.0006, pH 1 vs. pH 7). Semi-automated computerized image analysis was then performed to measure swelling of the particles. We constructed a glass continuous-flow cell that allowed stationary particles and real-time photography. Using digitized optical measurements there was no difference (p > 0.8) between the swelling after 1 h of pH 1 or 7 solutions (60.2 +/- 14.8% vs. 59.5 +/- 9.8% increase in diameter). Our findings support the importance of transient acid exposure in enhancing phosphate binding, due to increased protonated sites rather than by more swelling. Patients with acquired or pharmacologic achlorhydria would not benefit from this unexpected in vivo reaction. Possibly manufacturing sevelamer with a higher degree of protonation or administering it with appropriately acidic vehicles or beverages remains to be investigated.

[Relationship between sevelamer HCl and vascular calcification].[Pubmed:17339744]

Clin Calcium. 2007 Mar;17(3):392-8.

The Kidney Disease Outcomes Quality Initiative (K/DOQI) issued "Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease", in which it is recommended that the level of intact parathyroid hormone (i-PTH) should be kept at 150 - 300 pg/mL, the serum phosphorus (P) level at 3.5 - 5.5 mg/dL, and the serum calcium (Ca) level within the normal range of laboratory values (8.4 - 9.5 mg/mL, as close to the lower limit as possible). In developing these guidelines, the K/DOQI apparently considered the recently established fact that control of Ca, P and PTH influences not only the development of bone lesions but also patient prognostic factors such as arteriosclerosis, ectopic calcification, and cardiovascular complications, as well as the development of various vitamin D products and analogues and new P adsorbents. The Japanese guidelines also emphasize the control of P and Ca, rather than PTH. Therefore Phosphorus control is a primary goal in the care of patients with end-stage renal disease. We inspect the relationship between Vascular calcification and Sevelamer HCl, a non-aluminium, non-calcium, non-absorbed phosphate binder.

Spontaneous carbonate formation in an amorphous, amine-rich, polymeric drug substance: sevelamer HCl product quality.[Pubmed:22700351]

J Pharm Sci. 2012 Aug;101(8):2681-5.

Spectral differences among multiple manufacturers/lots of Sevelamer HCl were observed by Fourier transform infrared spectroscopy, and further characterization was performed to identify the cause for these differences. The drug substance is a polymer that possesses a large molecular weight, is amorphous, and is practically insoluble in both water and organic solvents. Thus, solid-state characterization methods (spectroscopic and thermal) were required to identify and characterize differences among the samples to assess possible differences in product quality. (1)(3)C cross-polarization-magic-angle-spinning nuclear magnetic resonance spectroscopy of Sevelamer HCl substances demonstrated the presence of a carbonyl-containing species, which was attributed to a carbonate impurity among samples. Stability studies demonstrated that this carbonate impurity formed spontaneously upon exposure of the drug substance to atmospheric water vapor and carbon dioxide, even under ambient conditions. Mechanistically, this behavior likely arises from the large number of primary and secondary amine groups, the hygroscopicity of the HCl salt, and a high degree of molecular mobility due to the amorphous nature of the drug substance.

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.[Pubmed:21705467]

Nephrol Dial Transplant. 2012 Feb;27(2):505-13.

BACKGROUND: Atherosclerosis and vascular calcification (VC) progression in chronic kidney disease is favored by disturbances of mineral metabolism. We compared the effect of phosphate binder lanthanum (La) carbonate with sevelamer-HCl on atherosclerosis, VC and bone structure and function in mice with chronic renal failure (CRF). METHODS: Apolipoprotein E-deficient (apoE(-/-)) mice were randomized to one non-CRF and three CRF groups, fed with standard diet (one non-CRF and one CRF) or diet supplemented with either 3% lanthanum carbonate (La3%) or 3% sevelamer-HCl (Sev3%). RESULTS: Both La3% and Sev3% supplemented CRF mice displayed a decrease of serum phosphorus, calcification at both intimal and medial aortic sites and atherosclerosis. This was associated with a reduction of plaque Type I collagen expression by both binders and of positive nitrotyrosine staining in response to sevelamer-HCl only. Increased mineral apposition and bone formation rates in unsupplemented CRF mice were reduced by Sev3% but not by La3%. CONCLUSIONS: The beneficial effects of La carbonate and sevelamer-HCl on the progression of VC and atherosclerosis in CRF mice could be mainly due to a decrease in phosphate retention and likewise a reduction of arterial Type I collagen expression. The effect of La carbonate differed from that of sevelamer-HCl in that it did not appear to exert its vascular effects via changes in oxidative stress or bone remodeling in the present model.

Description

Sevelamer hydrochloride is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

Keywords:

Sevelamer HCl,152751-57-0,Natural Products, buy Sevelamer HCl , Sevelamer HCl supplier , purchase Sevelamer HCl , Sevelamer HCl cost , Sevelamer HCl manufacturer , order Sevelamer HCl , high purity Sevelamer HCl

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: